| Q57464304 | ALSUntangled No. 26: Lunasin |
| Q92723464 | Are Circulating Cytokines Reliable Biomarkers for Amyotrophic Lateral Sclerosis? |
| Q37914155 | Astrocytes and microglia: responses to neuropathological conditions |
| Q59808726 | Biomarker Supervised G-CSF (Filgrastim) Response in ALS Patients |
| Q39413097 | Biomarkers in Neurodegenerative Diseases |
| Q37944427 | Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations |
| Q33893515 | Biomarkers in frontotemporal lobar degenerations--progress and challenges |
| Q33767845 | Blood biomarkers for amyotrophic lateral sclerosis: myth or reality? |
| Q38822774 | Characterization of Gene Expression Phenotype in Amyotrophic Lateral Sclerosis Monocytes. |
| Q64118808 | Circulating Cytokines Could Not Be Good Prognostic Biomarkers in a Mouse Model of Amyotrophic Lateral Sclerosis |
| Q34792280 | Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. |
| Q35957868 | Complex Inflammation mRNA-Related Response in ALS Is Region Dependent |
| Q38262690 | Disease origin and progression in amyotrophic lateral sclerosis: an immunology perspective. |
| Q39887929 | Distribution, differentiation, and survival of intravenously administered neural stem cells in a rat model of amyotrophic lateral sclerosis. |
| Q27498993 | Does neuroinflammation fan the flame in neurodegenerative diseases? |
| Q35058419 | Early gene expression changes in spinal cord from SOD1(G93A) Amyotrophic Lateral Sclerosis animal model |
| Q37440127 | Effects of facial nerve axotomy on Th2- and Th1-associated chemokine expression in the facial motor nucleus of wild-type and presymptomatic mSOD1 mice. |
| Q34425189 | Elevated serum ferritin is associated with reduced survival in amyotrophic lateral sclerosis |
| Q36182073 | Elucidation of Relevant Neuroinflammation Mechanisms Using Gene Expression Profiling in Patients with Amyotrophic Lateral Sclerosis |
| Q37694392 | Evaluating the levels of CSF and serum factors in ALS |
| Q39176680 | Exosomes: Origins and Therapeutic Potential for Neurodegenerative Disease |
| Q39033841 | Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis |
| Q38101089 | From frontotemporal lobar degeneration pathology to frontotemporal lobar degeneration biomarkers. |
| Q38856405 | Further development of biomarkers in amyotrophic lateral sclerosis. |
| Q38845041 | Glial biomarkers in human central nervous system disease |
| Q35806256 | Humoral factors in ALS patients during disease progression. |
| Q38170060 | Immunological aspects in amyotrophic lateral sclerosis |
| Q51519602 | Impaired activation of ALS monocytes by exosomes. |
| Q37487611 | Increased Expressions of Plasma Galectin-3 in Patients with Amyotrophic Lateral Sclerosis |
| Q38613326 | Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study |
| Q37380290 | Increased prevalence of autoimmune disease within C9 and FTD/MND cohorts: Completing the picture |
| Q36981069 | Increased ratio of circulating neutrophils to monocytes in amyotrophic lateral sclerosis |
| Q38629714 | Inflammatory role of dendritic cells in Amyotrophic Lateral Sclerosis revealed by an analysis of patients' peripheral blood |
| Q91688794 | Influence of Lineage-Negative Stem Cell Therapy on Articulatory Functions in ALS Patients |
| Q37221027 | Interleukin-6, MCP-1, IP-10, and MIG are sequentially expressed in cerebrospinal fluid after subarachnoid hemorrhage. |
| Q35917735 | Involvement of metabotropic glutamate receptor 5, AKT/PI3K signaling and NF-κB pathway in methamphetamine-mediated increase in IL-6 and IL-8 expression in astrocytes. |
| Q41874688 | MCP-1/CCR2 signaling-mediated astrocytosis is accelerated in a transgenic mouse model of SOD1-mutated familial ALS |
| Q34344992 | Mechanisms, models and biomarkers in amyotrophic lateral sclerosis |
| Q37592030 | Microglia in ALS: the good, the bad, and the resting |
| Q37952528 | Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis |
| Q36437332 | Motor neuron-immune interactions: the vicious circle of ALS. |
| Q35138815 | Multisite comparison of high-sensitivity multiplex cytokine assays |
| Q34370894 | Novel CSF biomarkers for frontotemporal lobar degenerations |
| Q35592875 | On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia |
| Q58608796 | Palm Fruit Bioactives modulate human astrocyte activity in vitro altering the cytokine secretome reducing levels of TNFα, RANTES and IP-10 |
| Q33676258 | Pathology of callosal damage in ALS: An ex-vivo, 7 T diffusion tensor MRI study |
| Q38094970 | Peripheral inflammation in neurodegeneration. |
| Q34299611 | Possible association between expression of chemokine receptor-2 (CCR2) and amyotrophic lateral sclerosis (ALS) patients of North India |
| Q94450925 | Potential of activated microglia as a source of dysregulated extracellular microRNAs contributing to neurodegeneration in amyotrophic lateral sclerosis |
| Q35863912 | Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist. |
| Q34640800 | Progress in therapy development for amyotrophic lateral sclerosis |
| Q38058054 | Proteome analysis of body fluids for amyotrophic lateral sclerosis biomarker discovery. |
| Q26750630 | Redox Imbalance and Viral Infections in Neurodegenerative Diseases |
| Q52558375 | Safety and Feasibility of Lin- Cells Administration to ALS Patients: A Novel View on Humoral Factors and miRNA Profiles. |
| Q48258033 | Sigma-1 Receptor in Motoneuron Disease |
| Q94561279 | The Peripheral Immune System and Amyotrophic Lateral Sclerosis |
| Q35238394 | The Role of immune and inflammatory mechanisms in ALS. |
| Q33961751 | The application of biomarkers in clinical trials for motor neuron disease |
| Q33633778 | The role of oxidative stress in degeneration of the neuromuscular junction in amyotrophic lateral sclerosis |
| Q26861263 | The role of the immune system in neurodegenerative disorders: Adaptive or maladaptive? |
| Q36878198 | The wobbler mouse, an ALS animal model |
| Q36733981 | Use of biomarkers in ALS drug development and clinical trials |
| Q38088747 | What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 2: chronic progressive and relapsing disease. |
| Q58742056 | YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression |